XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Payments
 6 Months Ended
Oct. 31, 2021
Share-based Payment Arrangement [Abstract]  
Share-Based Payments Share-Based Payments
 
The Company has in place a 2010 Equity Incentive Plan, 2008 Equity Incentive Plan and 2021 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.
 
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
October 31,		Six Months Ended
October 31,
 2021202020212020
General and administrative$48 $10 $219 $57 
Sales and marketing45 49 96 97 
Research and development8 5 14 9 
Cost of oncology services33 21 85 42 
Total stock-based compensation expense$134 $85 $414 $205 

Stock Option Grants
 
Black-Scholes assumptions used to calculate the fair value of options granted during the three and six months ended October 31, 2021 and 2020 were as follows:
 
Three Months Ended
October 31,		Six Months Ended
October 31,
 2021202020212020
Expected term in years
—
6
6
6
Risk-free interest rates
—%
0.27%
0
0.82%-—%
0.27%-0.39%
Volatility
—%
72.83%
65.94%-66.21%
72.64%-72.83%
Dividend yield—%—%—%—%
 
The weighted average fair value of stock options granted during the three and six months ended October 31, 2020 was $7.05 and $7.29, respectively. There was no options granted during the three months ended October 31, 2021. The weighted average fair value of stock options granted during the six months ended October 31, 2021 was $5.33.
The Company’s stock options activity for the six months ended October 31, 2021 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20211,618,231 35,415 1,653,646 $3.96 5.42$11,384,000 
Granted82,532 3,000 85,532 9.01 9.65
Exercised(82,078)— (82,078)1.91 
Forfeited(12,500)— (12,500)6.74   
Canceled(4,672)— (4,672)3.36 
Expired— (5,000)(5,000)9.60   
Outstanding, October 31, 20211,601,513 33,415 1,634,928 4.29 5.27$9,246,000 
Vested and expected to vest as of October 31, 20211,601,513 33,415 1,634,928 4.29 5.27$9,246,000 
Exercisable as of October 31, 20211,296,094 4,584 1,300,678 3.69 4.51$8,189,000